株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ポイントオブケア診断市場予測:主要企業の将来的展望

The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies

発行 Visiongain Ltd 商品コード 299052
出版日 ページ情報 英文 308 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=148.54円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ポイントオブケア診断市場予測:主要企業の将来的展望 The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies
出版日: 2014年04月09日 ページ情報: 英文 308 Pages
概要

ポイントオブケア診断市場には多くの機会が存在しています。世界的に既存の技術および製品の導入が広がることにより、同業界を刺激してもいます。世界のポイントオブケア診断市場の収益は2014年に172億米ドルに達すると予測されています。今後も2024年まで安定した成長を見せる見込みです。

当レポートでは、世界のポイントオブケア診断市場について調査し、2024年までの市場収益予測、国別動向、主要企業のプロファイルなどをまとめ、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 体外診断(IVD)およびポイントオブケア(POC)診断のイントロダクション

  • 体外診断検査とは
  • 体外診断の分類
  • IVDおよびPOC市場に関する法規制
  • IVD診断およびPOC診断に関する法規制
  • ポイントオブケア診断の使用動向
  • ポイントオブケア診断の長所と短所

第3章 ポイントオブケア診断市場

  • 当レポートの範囲
  • IVD市場におけるポイントオブケア診断
  • 世界のポイントオブケア診断市場
  • 世界のIVD市場売上予測
  • 世界の臨床診断市場予測
  • 世界のポイントオブケア診断市場売上予測
  • POC診断薬市場
  • ポイントオブケア診断市場の範囲
  • どのセグメントが最大の可能性をもっているか

第4章 主な国と地域

  • 世界のIVD市場の地域別内訳:国別売上予測
  • 世界のポイントオブケア診断市場の地域別内訳
  • 世界のPOC診断市場の地域別予測
  • 2024年までの地域別市場シェアの変化
  • 米国市場
  • 主要な欧州市場
  • 日本市場
  • BRICK諸国市場
  • その他

第5章 世界の血糖値検査市場

第6章 世界の凝固検査市場

第7章 世界の心臓マーカー検査市場

第8章 世界の感染症検査市場

第9章 世界の妊娠検査市場

第10章 世界のコレステロール検査市場

第11章 ポイントオブ診断市場における主要企業

  • 2014年の主要なPOC診断企業
  • Roche
  • Abbott
  • Siemens
  • Alere Inc
  • その他の企業

第12章 ポイントオブ診断市場の定性的分析

第13章 専門家の見解

第14章 結論

図表

目次

Point of care diagnostics - discover technological and commercial prospects

What does the future hold for the point of care diagnostics market? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 308 page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT, Porter's Five Forces and PESTEL), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:

  • Dr. Terenzio Facchinetti, Director Business Development, UL International GmbH
  • Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies (GHS), USA
  • Dr. David Huckle, President and CEO of Adams Business Associates (ABA), UK
  • Dr. Stephan Cohen-Bacrie, Co-director of the Multi-site Laboratory of Immunohematology and Immunogenetics, French Blood Establishment

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of seven world-level submarkets to 2024:

  • Blood glucose testing market
  • Coagulation testing market
  • Cardiac marker testing market
  • Infectious diseases testing market
  • Pregnancy testing market
  • Cholesterol testing market
  • Other point of care diagnostics markets

In general, each submarket is further segmented by components and discussions for leading regional markets within each submarket are also provided.

Our investigation shows business research and analysis with individual revenue forecasts and discussions. How will the point of care diagnostic markets expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects in the leading regions and countries?

Events and progress worldwide will influence the market. In our study you will find individual revenue forecasts to 2024 for 15 national markets:

  • US
  • Japan
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Brazil
  • Russia
  • India
  • China
  • South Korea
  • RoW

Many opportunities exist within the point of care diagnostics market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Additionally, you will find individual revenue forecasts to 2024 for 15 leading IVD national markets:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Netherlands
  • Belgium
  • Switzerland
  • Japan
  • China
  • India
  • South Korea
  • Brazil
  • Russia
  • Row

Leading companies and potential for market growth

Overall world revenue for the point of care diagnostics market will reach $17.2bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what organisations hold greatest potential. See profiles of four leading companies, including these:

  • Roche
  • Abbott
  • Siemens
  • Alere

In general, a company profile gives you the following information:

  • Overview of the company, including its history in the market
  • Revenue forecasts from 2014 to 2024
  • Discussion of a company's activities and outlook including descriptions of leading products
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

What issues will affect the point of care market?

Our new report discusses issues and events affecting the point of care market. You will find discussions, including qualitative analyses:

  • An ever-growing patient population with chronic diseases
  • An aging population
  • Globalisation of infectious diseases and associated public health concerns
  • Increasing demand for better monitoring and control of diseases
  • Telehealth and remote communications between diagnostics and laboratories
  • Global focus on personalised medicine

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies report helps you

In summary, our 307 page report gives you the following knowledge:

  • Revenue forecasts to 2024 for the overall world point of care diagnostics market and 7 submarkets - discover the industry's prospects, finding promising places for investments and revenues
  • Assessment of leading companies, and others, discovering activities and outlooks
  • Market forecasting to 2024 for 15 leading regions and countries in the POC diagnostics market and IVD market - USA, Japan, Germany, France, UK, Spain, Italy, Netherlands, Belgium, Switzerland, Brazil, Russia, China, India, South Korea and RoW.
  • View opinions from our survey, seeing 4 interviews with leading authorities
  • Investigation of competition and opportunities influencing sales
  • Discussion of what stimulates and restrains the point of care diagnostics market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

visiongain's study is for everybody needing commercial analyses for the point of care diagnostics market. You find data, trends and predictions. Please order our report now.

Table of Contents

1. Executive Summary

  • 1.1 The Point of Care (POC) Diagnostics Market Highlights
  • 1.2 Chapter Outlines
    • 1.2.1 Aims, Scope and Format of the Report
  • 1.3 Research and Analysis Methods

2. Introduction to In-Vitro Diagnostics and POC Diagnostics

  • 2.1 What are In Vitro Diagnostic (IVD) Tests?
  • 2.2 Classifying In Vitro Diagnostics
    • 2.2.1 FDA Classifications
    • 2.2.2 IVD Classification in Australia
    • 2.2.3 EDMA Classification
      • 2.2.3.1 Clinical Chemistry: Not To Be Discounted
      • 2.2.3.2 Immunochemistry
      • 2.2.3.3 Haematology
      • 2.2.3.4 Microbiology
      • 2.2.3.5 Genetic Testing
      • 2.2.3.6 Point Of Care Diagnostics: The Most Prominent Type
  • 2.3 Diagnostics Regulation of the IVD and POC Market
    • 2.3.1 FDA and CLIA Regulation of IVD and POC Tests
    • 2.3.2 Regulation of IVD/POC Diagnostics in the EU: The EC (European Commission) Classification
  • 2.4 Regulation for In-Vitro Diagnostics and POC Diagnostics
    • 2.4.1 Top Ten Challenges in Regulation for In-Vitro Diagnostics
    • 2.4.2 Device Excise Tax: A Threat to the Diagnostics Manufacturers
  • 2.5 Uses of Point of Care (POC) Diagnostics
  • 2.6 Advantages and Disadvantages of POC Diagnostics

3. The Point of Care Diagnostics Market, 2014-2024

  • 3.1 Scope of this Report
  • 3.2 Point of Care Diagnostics in the IVD Market, 2013
  • 3.3 The World Point of Care Diagnostics Market in 2013
    • 3.3.1 Self Testing Constituted the Largest Segment in the POC Market by the Point of Delivery
    • 3.3.2 Point of Care Diagnostics Market Segmentation
  • 3.4 The Global IVD Market: Sales Forecast, 2014-2024
    • 3.4.1 Which Segments Will Drive the Global IVD Market in the Next 10 Years?
  • 3.5 The Global Clinical Diagnostics Market Forecast, 2014-2024
  • 3.6 The Global Point of Care Diagnostics Market: Sales Forecast 2014-2024
    • 3.6.1 The Drive of Personalised Medicine
  • 3.7 Market for POC Diagnostics Products: Leading Segments to 2024
    • 3.7.1 Breakdown of the World Point of Care Diagnostics Main Submarkets: Changing Shares 2014-2024
    • 3.7.2 Blood Glucose Testing Market Forecast 2014-2024
    • 3.7.3 Infectious Diseases Testing Market Forecast 2014-2024
    • 3.7.4 Rapid Coagulation Testing Market Forecast 2014-2024
    • 3.7.5 Rapid Cardiac Marker Testing Market Forecast 2014-2024
    • 3.7.6 Cholesterol Testing Market Forecast 2014-2024
    • 3.7.7 Pregnancy Testing Market Forecast 2014-2024
    • 3.7.8 Other Segments Market Forecast 2014-2024
      • 3.7.8.1 Cancer Diagnostics Will Be a Major Driver for This Segment
      • 3.7.8.2 The Haematology Market Will Be Driven by Blood Gas Tests
      • 3.7.8.3 A Recently Discovered Biomarker for Sepsis Can Set The Potential For A Future Rapid Blood Test
  • 3.8 Scope of the Point of Care Diagnostics Market
  • 3.9 Which Point of Care Diagnostic Segment Holds the Greatest Potential?
    • 3.9.1 The Point of Care Diagnostics Market: Drivers and Restraints 2014-2024

4. Leading National Point of Care Diagnostics Markets 2014-2024

  • 4.1 Regional Breakdown of the World IVD Market: Sales Forecast by Country 2014-2024
  • 4.2 Regional Breakdown of the World Point of Care Diagnostics Market in 2013
  • 4.3 The World POC Diagnostics Market: Regional Forecasts 2014-2024
  • 4.4 How Will Regional Market Shares Change to 2024?
  • 4.5 The US POC Diagnostics Market, 2013
    • 4.5.1 The US Will Still Dominate the POC Diagnostics Market in 2024
    • 4.5.2 The US POC Diagnostics Market Forecast 2014 - 2024
    • 4.5.3 Healthcare Expending in the US
    • 4.5.4 The US POC Diagnostics Market: Drivers and Restraints
  • 4.6 The Leading European POC Diagnostics Markets: Sales Forecasts 2014-2024
    • 4.6.1 Variation in the European POCT Markets, 2014-2024
    • 4.6.2 The German POC Diagnostics Market Forecast, 2014-2024
    • 4.6.3 The UK POC Diagnostics Market Forecast 2014-2024
    • 4.6.4 The French POC Diagnostics Market Forecast 2014-2024
    • 4.6.5 The Italian POC Diagnostics Market Forecast 2014-2024
    • 4.6.6 The Spanish POC Diagnostics Market Forecast 2014-2024
    • 4.6.7 The Netherlands POC Diagnostics Market Forecast 2014-2024
    • 4.6.8 The Belgian POC Diagnostics Market Forecast 2014-2024
    • 4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024
  • 4.7 The Japanese POC Diagnostics Market Forecast 2014-2024
    • 4.7.1 The Japanese POC Diagnostics Market Overview 2014-2024
  • 4.8 The BRICK Nations POC Diagnostics Market
    • 4.8.1 The BRICK Nations POC Diagnostics Market: Overview
    • 4.8.2 How Will BRICK Market Shares Change to 2024?
    • 4.8.3 The BRICK Nations POC Diagnostics Market Forecast 2014-2014
      • 4.8.3.1 The Chinese POCT Market Overview: Advances in China Lead to Expansion of the Market 4.8.3.1.1 The Chinese POC Diagnostics Market Forecast 2014-2024
      • 4.8.3.2 The Indian POC Diagnostics Market Overview
        • 4.8.3.2.1 The Indian POC Diagnostics Market Forecast 2014-2024
      • 4.8.3.3 The South Korean POC Diagnostics Market Forecast 2014-2024
      • 4.8.3.4 The Brazilian POC Diagnostics Market Forecast 2014-2024
      • 4.8.3.5 The Russian POC Diagnostics Market Forecast 2014-2024
  • 4.9 Rest of the World POC Diagnostics Markets Forecasts 2014-2024
    • 4.9.1 Further Insights: Point of Care Diagnostics Approach for Developing Countries

5. Global Blood Glucose Testing Market, 2014-2024

  • 5.1 POC Blood Glucose Testing Market Overview
  • 5.2 Global POC Blood Glucose Testing Market, 2013
  • 5.3 POC Blood Glucose Testing Market Forecast 2014-2024
    • 5.3.1 POC Blood Glucose Testing Market by Type of Meter
    • 5.3.2 POC Blood Glucose Testing Market Segment by Components
      • 5.3.2.1 POC Blood Glucose Testing Devices Currently Available in the Market, 2014
    • 5.3.3 Leading Regional Markets in the POC Blood Glucose Testing Market, 2013
    • 5.3.4 Leading Companies in the POC Blood Glucose Testing Market, 2014
      • 5.3.4.1 Other Companies in the POC Blood Glucose Testing Market: Recent Advances
    • 5.3.5 Market Prospects to 2024: Which Product Will Lead the Market?
      • 5.3.5.1 Advantages and Disadvantages of the Current CGM Tests in the Market
  • 5.4 Drivers and Restraints for the POC Blood Glucose Testing Market, 2014-2024

6. Global Coagulation Testing Market, 2014-2024

  • 6.1 Global POC Coagulation Testing Market: Overview
  • 6.2 Global POC Coagulation Testing Market in 2013
    • 6.2.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market
  • 6.3 Products Available in the POC Coagulation Testing Market, 2014
    • 6.3.1 Patient Self Testing is a Fastest Growing Segment
  • 6.4 POC Coagulation Testing Market Segment by Components
    • 6.4.1 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market
  • 6.5 POC Coagulation Testing Market by Type of Drug
    • 6.5.1 Anticoagulants
    • 6.5.2 Heparins
    • 6.5.3 Vitamin K Antagonists
    • 6.5.4 Direct Thrombin Inhibitors
    • 6.5.5 Direct Factor Xa Inhibitors
  • 6.6 The POC Coagulation Testing Market by Regions, 2013
  • 6.7 POC Coagulation Testing Market Forecast 2014-2024
  • 6.8 Leading Companies in the POC Coagulation Testing Market, 2014
    • 6.8.1 Roche Dominated the POC Coagulation Testing Market with CoaguChek XS System in 2013
    • 6.8.2 Market Prospects to 2024: Who Will Be The Leading Product?
  • 6.9 Drivers and Restraints for the POC Coagulation Testing Market, 2014-2024

7. Global Cardiac Marker Testing Market, 2014-2024

  • 7.1 Cardiac Marker Diagnostic Testing Market: Overview
    • 7.1.1 The Majority of Cardiac Marker Testing is Conducted in Critical Care Settings
  • 7.2 The Global Cardiac Marker Diagnostic Testing Market 2013
  • 7.3 Cardiac Marker Diagnostic Testing Market Forecast 2014-2024
    • 7.3.1 Leading Regional Markets in the Cardiac Marker Diagnostic Testing, 2013
      • 7.3.1.1 Global Deaths Due to CVD in High, Middle and Low Income Countries, 2014
    • 7.3.2 Leading Companies in the Cardiac Marker Diagnostic Testing Market, 2014
    • 7.3.3 Cardiac Marker Diagnostic Tests Currently Under Development, 2014
      • 7.3.3.1 cobas h232 Cardiac Marker (Roche)
      • 7.3.3.2 QL Care Analyzer (CardioGenics)
      • 7.3.3.3 Handheld Device (bioMerieux/Royal Philips Electronics)
    • 7.3.4 Cardiac Marker Diagnostic Testing Market: Leading Products
    • 7.3.5 Which Company is Dominating the Market?
    • 7.3.6 A Leading Product: Abbott's i-STAT
  • 7.4 Drivers and Restraints for the Cardiac Marker Diagnostic Testing Market, 2014-2024
    • 7.4.1 Challenges for the New Entrants in the Cardiac Markers Diagnostic Testing Market

8. Global Infectious Diseases Testing Market, 2014-2024

  • 8.1 POC Infectious Diseases Testing Market: Overview
  • 8.2 Global POC Infectious Diseases Testing Market, 2013
    • 8.2.1 Breakdown of the POC Infectious Diseases Testing Market by Diseases, 2013
      • 8.2.1.1 Influenza/Flu
      • 8.2.1.2 HIV
      • 8.2.1.3 Hepatitis
      • 8.2.1.4 Tuberculosis
      • 8.2.1.5 Sexually Transmitted Diseases
  • 8.3 The POC Infectious Diseases Testing Market: Leading Products 2014
    • 8.3.1 HIV Leading POC Diagnostics Products, 2014
    • 8.3.1.1 HIV Diagnostics Kits Approved by the FDA, 2014
    • 8.3.2 The HIV Rapid Testing Market in the US, 2014
    • 8.3.3 HIV POC Tests Pipeline, 2014
    • 8.3.4 Driving Factors for Growth of HIV Rapid Testing: Past and Future
  • 8.4 The Hepatitis POC Testing Market
    • 8.4.1 First Rapid HCV Test Approved in the US
    • 8.4.2 The Influenza POC Testing Market and Leading Companies, 2014
    • 8.4.3 Driving Factors for Growth of Hepatitis Rapid Testing
    • 8.4.4 POC Infectious Diseases Recent Trends
      • 8.4.4.1 OraQuick Marker, OraSure Technologies: First OTC Home-Use Rapid HIV Test Approved by the FDA
      • 8.4.4.2 Determine HIV-1/2 Ag/Ab Combo Test, Alere: First Rapid Diagnostic Test to Detect Both HIV-1 Antigen And HIV-1/2 Antibodies
    • 8.4.5 Leading Regional Markets in the POC Infectious Diseases Testing
    • 8.4.5.1 Infectious Diseases POC Testing: Regional Markets in 2013
  • 8.5 Infectious Diseases POC Testing Market: Leading Companies 2014
  • 8.6 The POC Infectious Diseases Testing Market Forecast, 2014-2024
  • 8.7 Drivers and Restraints for the POC Infectious Diseases Testing Market, 2014-2024

9. Global Pregnancy Testing Market, 2014-2024

  • 9.1 The POC Pregnancy Testing Market: Overview
  • 9.2 Global POC Pregnancy Testing Market, 2013
  • 9.3 The POC Pregnancy Testing Market Forecast 2014-2024
    • 9.3.1 The POC Pregnancy Testing Market: Leading Products 2014
    • 9.3.2 Leading Companies in the POC Pregnancy Testing Market, 2014
  • 9.4 Drivers and Restraints for the POC Pregnancy Testing Market, 2014-2024

10. Global Cholesterol Testing Market, 2014-2024

  • 10.1 Global POC Cholesterol Testing Market: Overview
  • 10.2 The Global POC Cholesterol Testing Market in 2013
  • 10.3 The POC Cholesterol Testing Market Forecast 2014-2024
    • 10.3.1 POC Cholesterol Testing Biomarkers: Overview
    • 10.3.2 The POC Cholesterol Testing Market by Components
    • 10.3.3 Recent Developments in the POC Cholesterol Testing Market, 2014
      • 10.3.3.1 New Product 2014: Roche's Accutrend Plus
    • 10.3.4 POC Cholesterol Testing Market: Considerations in Production
  • 10.4 Drivers and Restraints for the POC Cholesterol Testing Market, 2014-2024

11. Leading Companies in the POC Diagnostics Market, 2014

  • 11.1 Leadng POC Diagnostics Companies in 2014
  • 11.2 Roche: Overview
    • 11.2.1 Roche: Global Presence
    • 11.2.2 Roche Diagnostics, 2014-2024
      • 11.2.2.1 Roche Business Performance within the IVD Market, 2013
      • 11.2.2.2 Roche Diagnostics Market Forecast 2014-2024
    • 11.2.3 Roche Diagnostics: Key Launches Planned for 2014
    • 11.2.4 Roche Diagnostics: POC Product Portfolio
    • 11.2.5 Roche: Recent M&A Activity and Strategic Collaborations
  • 11.3 Abbott: Continuously Transforming to Meet the Changing Needs
    • 11.3.1 Abbott: Market Leader in the Coronary DES Sector
    • 11.3.2 Abbott Diagnostics: Overview, 2013
      • 11.3.2.1 Abbott Diagnostics: Leading Point-of-Care Platform
    • 11.3.3 Abbott's Fast Growing Diagnostics Division: Sales Forecast 2014-2024
    • 11.3.4 Abbott Portfolio Sales and Recent Performance Analysis
    • 11.3.5 Abbott: The i-STAT System
      • 11.3.5.1 Recent M&A Activity and Strategic Collaborations
        • 11.3.5.1.1 Abbott Laboratories Agreed to Acquire IDEV Technologies
        • 11.3.5.1.2 Collaboration with Merck
      • 11.3.5.2 Abbott IVD Segment: Strengths & Challenges
  • 11.4 Siemens: A Highly Diversified Company
    • 11.4.1 Siemens Healthcare: Prospects within the IVD Market
    • 11.4.2 Siemens Healthcare: Sales Forecast 2014-2024
    • 11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio
      • 11.4.3.1 Siemens Healthcare Diagnostics Recent Trends, 2014
      • 11.4.3.2 Recent M&A Activity and Strategic Collaborations
  • 11.5 Alere Inc: A Strong Player
    • 11.5.1 Alere Inc Performance Analysis in 2013
    • 11.5.2 Alere Inc: Performance in Geographic Markets in 2013
    • 11.5.3 Alere Inc.: Product Profile Overview
    • 11.5.4 Alere's Professional Diagnostics Market in 2013
    • 11.5.5 Product Profile Recent Trends, 2014
    • 11.5.6 Alere Market Forecast 2014-2024
    • 11.5.7 Alere: Recent M&A Activity and Strategic Collaborations
  • 11.6 Other Companies of Interest: Recent M&A Activity and Strategic Collaborations, 2014

12. Qualitative Analysis of the POC Diagnostics Market, 2014-2024

  • 12.1 Introduction
  • 12.2 Drivers and Restraints for the POC Diagnostics Market
    • 12.2.1 Commercial Drivers
    • 12.2.2 Commercial Restraints
  • 12.3 Strategic Review of the POC Diagnostics Market
  • 12.4 Pestel Analysis
    • 12.4.1 Political Factors
    • 12.4.2 Economic Factors
    • 12.4.3 Socio-Cultural Factors
    • 12.4.4 Technological Factors
    • 12.4.5 Environmental Factors
    • 12.4.6 Legal Factors
  • 12.5 P5F Analysis
    • 12.5.1 Competitive Rivalry
    • 12.5.2 Rivalry Among Competitors: [High] Diagnostics is a Promising Market
    • 12.5.3 Potential Entrants into the POC Diagnostics Market
      • 12.5.3.1 Threat of New Entrants: [Medium] Continuous Arousal of Innovations in the POCT Market
    • 12.5.4 Who Are The Latent Substitutes?
    • 12.5.5 Threat of Substitutes: [Medium]New Technologies Might Limit the Need to Monitor Diseases
    • 12.5.6 Vertical Integration With Suppliers and Buyers
      • 12.5.6.1 Power of Suppliers: [Medium] Increased Competition Outweigh Suppliers
      • 12.5.6.2 Power of Buyers: [High] Demand and Health Systems Will Go Hand by Hand
  • 12.6 SWOT Analysis and Strategies
    • 12.6.1 Strengths: Timing is First
    • 12.6.2 Weaknesses: Awaiting Expanded Reimbursement Options
    • 12.6.3 Opportunities: A Promising Market
    • 12.6.4 Threats: Unmet Needs in the Low-Middle Income Countries

13. Expert Opinions

  • 13.1 Interview with Dr. Terenzio Facchinetti, Director Business Development of UL Life and Health, UL International GmbH, Germany.
  • 13.1.1 Impact of Remote Access on the POCT Market
    • 13.1.2 UL's Life and Health Business Unit: A Global Independent Safety Science Company
    • 13.1.3 The Importance of Standardization and Regulations for the POC Market
    • 13.1.4 Recommendations for the Future of POC Diagnostics: What to Expect
  • 13.2 Interview with Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies (GHS), USA.
    • 13.2.1 Advantages of POC Diagnostics
    • 13.2.2 Restraints of POC Diagnostics
    • 13.2.3 About Genomic Healthcare Strategies
    • 13.2.4 US has the Highest Potential for the POC Diagnostics Market
    • 13.2.5 Remarkable Insights
  • 13.3 Interview with Dr. David Huckle, President and CEO of Adams Business Associates (ABA), UK.
    • 13.3.1 Remarkable Understanding on the POC Diagnostics Market
    • 13.3.2 The Expert's Perspective: Drivers and Restraints for POC Diagnostics
    • 13.3.3 Recommendations for the Future POC Diagnostics Market
    • 13.3.4 Further Insights from Dr. Huckle: Leading Companies
  • 13.4 Interview with Dr. Stéphan Cohen-Bacrie, Co-director of the Multi-site Laboratory of Immunohematology and Immunogenetics, French Blood Establishment, Burgundy-FrancheComté, France.
    • 13.4.1 The French POC Diagnostics Market: Experienced Perspective
    • 13.4.2 Restraints in the POC Diagnostics Market
    • 13.4.3 The Advantage of Molecular Diagnostics
    • 13.4.4 Innovations in Rural Africa: POC-labs
    • 13.4.5 R&D in Focus: The Syndromic Panels and Microfluidics-based Methods
    • 13.4.6 Where is the POC Diagnostics Market Heading?: An Expert's View

14. Conclusions

  • 14.1 Overview
  • 14.2 The POC Testing in the IVD Market
  • 14.3 The World POC Diagnostics Market Forecast 2014-2024
    • 14.3.1 Leading Regional Markets Forecast 2014-2024
  • 14.4 The World POC Diagnostics Market Forecast 2014-2024
  • 14.5 POC Diagnostic Segments: Positions in the Market 2014
    • 14.5.1 Current Advantages in POC Diagnostics
      • 14.5.1.1 Comparison with Laboratory Testing
    • 14.5.2 Leading POC Diagnostics Companies, 2014
  • 14.6 Commercial Drivers for the Adoption of POC Tests
    • 14.6.1 Commercial Restraints in the POC Diagnostics Market
  • 14.7 Challenges for POC Diagnostics
  • 14.8 The Future of the POC Diagnostics and Concluding Remarks

List of Tables

  • Table 2.1Types of Genetic In Vitro Diagnostic Tests Currently Available, 2013
  • Table 2.2 Advantages and Disadvantages of POC Diagnostics, 2014
  • Table 3.1 The IVD Diagnostics Market: Revenue ($bn) and Market Shares (%) by Segments, 2013
  • Table 3.2 The IVD Diagnostics Market: Revenue ($bn) and Market Shares (%) by Type of Delivery, 2013
  • Table 3.3 The POC Diagnostics Market: Revenue ($bn) and Market Shares (%) by Segments, 2013
  • Table 3.4 The IVD Diagnostics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 3.5 The IVD Diagnostics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segments, 2013-2024
  • Table 3.6 The Clinical Diagnostics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 3.7 The Global POC Diagnostics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 3.8 World POC Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2013-2024
  • Table 3.9 The Global POC Diagnostics Market: Shares (%), by Segment, 2013, 2018 and 2024
  • Table 4.1 IVD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), by Country, 2013-2024
  • Table 4.2 The POC Diagnostics Market: Revenue ($bn) and Market Shares (%) by Regional Markets, 2013
  • Table 4.3 POC Diagnostics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), by Region, 2013-2024
  • Table 4.4 The Global POC Diagnostics Market: Shares (%), by Regional Markets, 2013, 2018 and 2024
  • Table 4.5 US POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.6 European POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), by Country, 2013-2024
  • Table 4.7 The German POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.8 The UK POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.9 The French POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.10 The Italian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.11 The Spanish POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.12 The Netherlands POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.13 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.14 The Swiss POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.15 The Japanese POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.16 The BRICK Countries POC Diagnostics Market Forecasts: Sales Revenue ($bn), AGR (%) and CAGR (%), by Country, 2013-2024
  • Table 4.17 The Chinese POC Diagnostics Market Forecasts: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.18 The Indian POC Diagnostics Market Forecasts: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.19 The South Korean POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.20 The Brazilian POC Diagnostics Market Forecasts: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.21 The Russian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 4.22 ROW POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 5.1 Global POC Blood Glucose Testing Devices Market , Revenue ($bn) and Share (%), 2013
  • Table 5.2 The Global POC Blood Glucose Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 5.3 Global POC Blood Glucose Testing Devices Market, Revenue ($bn) and Shares (%), by Type of Meter, 2013
  • Table 5.4 Global POC Blood Glucose Testing Devices Market, Revenue ($bn) and Shares (%), by Components, 2013
  • Table 5.5 Retail Prices of the Blood Glucose Meters and Strips Currently Available in the Market, by Company, 2014
  • Table 5.6 Leading National Markets for the POC Blood Glucose Testing Market, Revenue ($bn) and Shares (%), 2013
  • Table 5.7 Main Product of the Diabetes Care Business Segment, Revenue ($bn) and Shares (%), by Leading Companies, 2013
  • Table 5.8 List of Some Other Companies in the POC Blood Glucose Testing Market, 2014
  • Table 5.9 Advantages of CGMs over Fingerstick Testing Systems, 2014
  • Table 5.10 Advantages and Disadvantages of the Currently Available CGM, by Product, 2014
  • Table 6.1 Global POC Coagulation Testing Market, Revenue ($bn) and Share (%), 2013
  • Table 6.2 List of Some Products in the POC Coagulation Testing Market for Self Testing and Professional Testing, 2014
  • Table 6.3 The PT/INR POC Testing Market, Revenue ($m) and Shares (%), by Point of Use, 2013
  • Table 6.4 The Price of Some PT/INR POC Testing Systems ($), 2014
  • Table 6.5 PT/INR POC Testing Market, Revenue ($m) and Shares (%), by Components, 2013
  • Table 6.6 The Global POC Coagulation Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 7.1 Global Cardiac Marker Diagnostic Testing Market, Revenue ($bn) and Share (%), 2013
  • Table 7.2 Time to Elevation for Some Cardiac Markers, 2014
  • Table 7.3 Clinical Use of the Cardiac Biomarkers, 2014
  • Table 7.4 The Global Cardiac Marker Diagnostic Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 7.5 Companies Developing Cardiac Biomarkers, 2014
  • Table 7.6 Leading Products in the Cardiac Marker Diagnostic Testing Market, by Company, 2014
  • Table 8.1 Global POC Infectious Diseases Testing Market, Revenue ($bn) and Share (%), 2013
  • Table 8.2 POC Infectious Disease Market: Revenues ($bn), by Disease, 2013
  • Table 8.3 Strengths and Limitations of Some Leading Products in the HIV Rapid Testing Market , 2014
  • Table 8.4 FDA Currently Approved HIV Diagnostic Kits Through Premarket Applications (PMAs), by Date of FDA Approval, 2014
  • Table 8.5 The US HIV Rapid Testing Market, Revenue ($m) and Shares (%), by Leading Products, 2013
  • Table 8.6 List of Some HIV POC Tests Under Development, 2014
  • Table 8.7 List of Some Products in the POC Hepatitis Testing Market, 2014
  • Table 8.8 List of Some Products in the Rapid Influenza Testing Market, 2014
  • Table 8.9 The Global POC Infectious Diseases Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 9.1 Global POC Pregnancy Testing Market, Revenue ($bn) and Share (%), 2013
  • Table 9.2 The Global POC Pregnancy Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 10.1 Global POC Cholesterol Testing Market, Revenue ($bn) and Share (%), 2013
  • Table 10.2 The Global POC Cholesterol Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 11.1 Roche Diagnostics: Revenue ($m) and Revenue Share (%), by Business Area, 2013
  • Table 11.2 Roche Diagnostics Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 11.3 Roche Diagnostics: Key Product Launches Planned for 2014
  • Table 11.4 Abbott Diagnostics: Revenues ($m) and Revenue Shares (%), by Business Segment, 2013
  • Table 11.5 Abbott Diagnostics Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 11.6 Siemens: Revenue ($m) and Revenue Shares (%), by Business Sectors, 2013
  • Table 11.7 Siemens Healthcare Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 11.8 Siemens Healthcare: Point of Care Testing Products Range, 2014
  • Table 11.9 Alere Inc. Revenue ($m) and Revenue Shares (%), by Business Segment, 2013
  • Table 11.10 Alere Inc. Revenue ($m) and Revenue Shares (%), by Geographic Location, 2013
  • Table 11.11 Alere Inc: Professional Diagnostics Product Portfolio Overview for Each Segment, 2014
  • Table 11.12 Description of the Product Portfolio for Alere Inc., 2014
  • Table 11.13 Alere Professional Diagnostics Segment: Revenue ($m) and Revenue Shares (%), by Group, 2013
  • Table 11.14 Alere Professional Diagnostics Forecast: Sales ($bn), AGR (%) and CAGR (%), 2013-2024
  • Table 12.1 SWOT Analysis of the POC Diagnostics Market, 2014-2024

List of Figures

  • Figure 3.1 Global IVD Market Shares (%) by Segment, 2013
  • Figure 3.2 Global IVD Market Revenues ($bn) for Clinical Diagnostics and POC Diagnostics Segments, 2013
  • Figure 3.3 Market Share (%) and Market Size ($bn) of Self Testing/OTC and Professional Testing in the POC Market, 2013
  • Figure 3.4 The POC Diagnostics Market: Shares (%) by Segments, 2013
  • Figure 3.5 Global IVD Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 3.6 The IVD Diagnostics Market Forecast: Revenue ($bn), by Segments, 2013-2024
  • Figure 3.7 The Clinical Diagnostics Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 3.8 The Global POC Diagnostics Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 3.9 World POC Diagnostics Market Forecast: Revenues ($bn), by Segment, 2013-2024
  • Figure 3.10 World POC Diagnostics Market: CAGR (%), by Segment, 2013-2024
  • Figure 3.11 The POC Diagnostics Market Shares (%), by Segments, 2013
  • Figure 3.12 The POC Diagnostics Market Shares (%), by Segments, 2018
  • Figure 3.13 The POC Diagnostics Market Shares (%), by Segments, 2024
  • Figure 3.14 The POC Diagnostics Market Shares (%), by Segments (excld. Blood Glucose Market), 2013-2024
  • Figure 3.15 Scope of The POC Diagnostics Market: Revenue ($bn) and CAGR (%), by Segments, 2013
  • Figure 3.16 The POC Diagnostics Market: Drivers and Restraints, 2014-2024
  • Figure 4.1 World POC Diagnostics Market: Revenue ($bn), by Regional Markets, 2013
  • Figure 4.2 POC Diagnostics Market: Sales Revenue ($bn), by Region, 2013- 2024
  • Figure 4.3 POC Diagnostics Sales Shares (%) in Leading Regional Markets, 2013
  • Figure 4.4 POC Diagnostics Sales Shares (%) in Leading Regional Markets, 2018
  • Figure 4.5 POC Diagnostics Sales Shares (%) in Leading Regional Markets, 2024
  • Figure 4.6 The US POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.7 US IVD Market: Drivers and Restraints, 2014-2024
  • Figure 4.8 European POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.9 The German POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.10 The UK POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.11 The French POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.12 The Italian POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.13 The Spanish POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.14 The Netherlands POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.15 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.16 The Swiss POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.17 The Japanese POC Diagnostics National Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.18 The BRICK Nations POC Diagnostics Market Shares (%), by Country, 2013
  • Figure 4.19 The BRICK Nations POC Diagnostics Market Shares (%), by Country, 2018
  • Figure 4.20 The BRICK Nations POC Diagnostics Market Shares (%), by Country, 2024
  • Figure 4.21 The BRICK Countries POC Diagnostics Market Forecasts: Sales Revenue ($bn) and AGR (%), by Country, 2013-2024
  • Figure 4.22 The Chinese POC Diagnostics Market Forecasts: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.23 The Indian POC Diagnostics Market Forecasts: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.24 The South Korean POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.25 The Brazilian POC Diagnostics Market Forecasts: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 4.26 The Russian POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024
  • Figure 5.1 The Global POC Blood Glucose Testing Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 5.2 Market Shares (%) of Fingerstick Testing and CGM Devices in the POC Blood Glucose Monitoring Market, 2013
  • Figure 5.3 Market Shares (%) of Devices, Test Strips and Other Devices in the POC Blood Glucose Testing Market, 2013
  • Figure 5.4 Market Shares (%) of Leading National Markets in the POC Blood Glucose Testing Market, 2013
  • Figure 5.5 Sales Revenues ($bn) for the Diabetes Care Business Segment, Revenue ($bn) and Shares (%), by Leading Companies, 2013
  • Figure 5.6 POC Blood Glucose Testing Market: Drivers and Restraints, 2014-2024
  • Figure 6.1 The PT/INR POC Testing Market by Point of Use, Market Share (%), 2013
  • Figure 6.2 PT/INR POC Testing Market Shares (%), by Components, 2013
  • Figure 6.3 The Global POC Coagulation Testing Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 6.4 The POC Coagulation Testing Market: Drivers and Restraints, 2014-2024
  • Figure 7.1 The Global Cardiac Marker Diagnostic Testing Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 7.2 Global Fraction of Deaths Due to Cardiovascular Diseases in High, Middle and Low Income Countries
  • Figure 7.3 Pipeline of Cardiac Markers Diagnostics Tests Currently in Development, 2014
  • Figure 7.4 Market Share (%) of cobas h232, i-STAT and RAMP in the Global Cardiac Marker Diagnostic Testing Market, 2013
  • Figure 7.5 Cardiac Marker Diagnostic Testing Market: Drivers and Restraints, 2014-2024
  • Figure 8.1 The POC Infectious Disease Market Shares (%), by Disease, 2013
  • Figure 8.2 Market Share (%) of Leading Products in the US HIV Rapid Testing Market, 2013
  • Figure 8.3 The Global POC Infectious Diseases Testing Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 8.4 POC Infectious Diseases Testing Market: Drivers and Restraints, 2014-2024
  • Figure 9.1 The Global POC Pregnancy Testing Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 9.2 The POC Pregnancy Testing Market: Drivers and Restraints, 2014-2024
  • Figure 10.1 The Global POC Cholesterol Testing Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 10.2 The POC Cholesterol Testing Market: Drivers and Restraints, 2014-2024
  • Figure 11.1 Roche Diagnostics: Revenues ($m) by Business Area, 2013
  • Figure 11.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2013
  • Figure 11.3 Roche Diagnostics Revenue Forecast: Sales ($bn) and AGR (%), 2013-2024
  • Figure 11.4 Abbott Diagnostics: Revenue ($m), by Business Segment, 2013
  • Figure 11.5 Abbott Diagnostics: Revenue Shares (%), by Business Segment, 2013
  • Figure 11.6 Abbott Diagnostics Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 11.7 Siemens: Revenue Shares (%), by Business Sector, 2013
  • Figure 11.8 Siemens Healthcare Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
  • Figure 11.9 Alere Inc. Revenue Shares (%), by Business Segment, 2013
  • Figure 11.10 Alere Inc. Revenue Shares (%), by Geographic Location, 2013
  • Figure 11.11 Alere Professional Diagnostics Segment: Revenue Shares (%), by Group, 2013
  • Figure 11.12 Alere Professional Diagnostics Forecast: Sales ($bn) and AGR (%), 2013-2024
  • Figure 12.1 Drivers and Restraints For The POC Diagnostics Market
  • Figure 12.2 Relationship Between PESTEL, PSF and SWOT
  • Figure 12.3 Porter's Five Forces Analysis of the POC Diagnostics Market, 2014-2024
  • Figure 13.1 The Factors That Can Limit the Growth of POC Diagnostics
  • Figure 14.1The Classification of POC Diagnostics
  • Figure 14.2 The World IVD Market: Shares (%), by Segments, 2013
  • Figure 14.3 The World POC Diagnostics Market Forecast, Revenue ($bn) and AGR (%) 2013-2024
  • Figure 14.4 The POC Diagnostics Regional Market Forecast: Revenue ($bn), by Regional Markets, 2014-2024
  • Figure 14.5 The World POC Diagnostics Regional Market Shares (%), by Country, 2013, 2018 and 2024
  • Figure 14.6 The World POC Diagnostics Market Forecast: Sales Revenue ($bn), by Segments, 2013-2024
  • Figure 14.7 Position in the Market for the POC Diagnostics Market: by Segments, 2013
  • Figure 14.8 Sales Revenue ($bn) of Some of the Leading POC Diagnostics Companies, 2013
  • Figure 14.9 SWOT Analysis Results for the Global POC Diagnostics Market, 2014-2024

Companies Listed

  • 1 Step Detect Associates
  • 3M
  • 3test
  • 77 Elektronika Kft
  • Abaxis Inc
  • Abbott
  • Abbott Diagnostics
  • Abbott Laboratories
  • Abbott Point of Care
  • AbbVie
  • AccuBioTech Co., Ltd.
  • Accumetrics
  • Accutech
  • Acon Laboratories
  • Acrongenomics Inc.
  • Adams Business Associates (ABA)
  • Advanced Care
  • Advanced Liquid Logic
  • Advanced MicrodevicesPvt. Ltd.
  • Aerscher Diagnostics
  • AgaMatrix Inc.
  • Agendia
  • Aimedics (Australia)
  • Akers Biomedical
  • Alere Inc.
  • Alfa Scientific Designs, Inc.
  • Alfa Wassermann Diagnostic Technologies, LLC
  • All Medicus
  • Alliance International Co., Ltd.
  • Amedica Biotech
  • American Bio Medica Corp
  • AmeriTek
  • Amgenix International Inc
  • AMICAS Corp
  • Ampcor
  • Analyticon Biotechnologies AG
  • Ani Biotech
  • Ani Biotech/Ani Laboratories
  • Answer
  • Apex Biotechnology Corp.
  • Applied Microarrays
  • ARJ Medical
  • ARKRAY, Inc.
  • Arlington Scientific, Inc.
  • Artron Laboratories
  • AspenBioPharma, Inc.
  • Astra Zeneca
  • Ativa Medical
  • Atlas Genetics
  • Atlas Link Biotech Co., Ltd.
  • Atonomics A/S
  • Audit Diagnostics
  • Autobio Diagnostics Co., Ltd.
  • Aventir Biotech
  • Aware Oral OTC - Calypte Biomedical
  • Axis-Shield plc
  • Axxin
  • AZOG, Inc.
  • B.R.A.H.M.S. AG
  • Bain Capital
  • Barr Pharmaceuticals
  • Bayer
  • BBI Healthcare
  • Bbraun
  • BC Partners
  • BD Biosciences
  • Beckman Access
  • Beckman Coulter Inc.
  • Becton, Dickinson and Company (BD)
  • Bio-AMD
  • Biofire Diagnostics
  • BioHelix Corporation
  • bioLytical Laboratories
  • BioMeditech Corporation
  • BioMerieux
  • Bionime
  • Bio-Rad Laboratories Inc.
  • BioSign
  • Biosite
  • Blackstone Group
  • Boditech
  • Boditechmed
  • Boehringer Ingelheim
  • Buying Solutions
  • C8 Medisensor
  • Calypte Biomedical Co
  • Cantimer
  • CardioGenics
  • Carlyle Group
  • Cepheid
  • CHEMBIO DIAGNOSTIC SYSTEMS, INC
  • Chugai Pharmaceuticals
  • Church & Dwight (CHD)
  • Clearview
  • CLIA laboratory
  • CoaguSense
  • Core Diagnostics
  • Dade Behring
  • Daktari Diagnostics
  • Danaher
  • Danaher Corporation
  • Decision Diagnostics Corp.
  • Dexcom
  • Diabetic Supply of Suncoast
  • Diagnostic Devices
  • Diagnostics for the Real World
  • DiME
  • e2v Biosensors
  • Early Pregnancy Tests.com
  • EIDIA
  • Eisai
  • EKF-diagnostic Gmb
  • Entegrion
  • Entra Health Systems
  • Epocal Inc
  • Expression Diagnostics
  • EY Laboratories
  • Fifty50 Medical
  • First Medical
  • Fisher Scientific
  • Focus Diagnostics
  • Fora Care
  • GeneDiagnostics Inc.
  • Genentech
  • General Life Biotechnology Ltd
  • Genesis Health Technology
  • Genomic Healthcare Strategies (GHS)
  • Genzyme
  • GlaxoSmtihKline (GSK)
  • Gluco Com
  • Grifols
  • Helena Laboratories
  • Helena Point of Care
  • Hema technologies
  • HemoCue
  • Hologic Inc
  • Home Diagnostics, Inc. (HDI)
  • Horiba
  • Ibis Biosciences
  • IDEV Technologies
  • IME-DC
  • Immucor
  • IND Diagnostics
  • Infopia
  • Innotrac
  • Insight Pharmaceuticals
  • Instrumentation Laboratory
  • Integrity Applications Ltd.
  • Inverness Medical Innovations (Alere)
  • IQuum
  • JANT Pharmacal Corporation
  • Johnson & Johnson (J&J)
  • Johnson & Johnson LifeScan
  • Johnson & Johnson's Ortho Clinical Diagnostics unit (OCD)
  • KKR & Co
  • Leeds and Partners
  • Lifescan Inc.
  • LifeSign
  • MBio Diagnostics
  • Mechanical Heart Valve Support Group
  • Medco Health Solutions
  • Medix Biochemica
  • Medmira Inc
  • Medtronic Ltd
  • Meikang Biotech
  • Menarini
  • Mendor
  • Merck
  • Meridian Bioscience
  • Micronics (acquired by Sony Corporation)
  • Mitsubishi Chemical
  • Mitsubushi Chemical Medience
  • MIZUHO MEDY Company
  • MobileLink
  • MyoCheck
  • NanoEntek
  • Nanogen
  • Nanomix, Inc.
  • Nanosphere, Inc.
  • Nestle
  • Nipro Diagnostics
  • Nova Biomedical
  • Novartis AG
  • Novescia Network of laboratories
  • Oak Tree International Holdings
  • Olympus
  • OnSight
  • OptiMedica Corporation
  • OraSure Technologies, Inc.
  • OrSense
  • Ortho-Clinical Diagnostics
  • Partec
  • Partec GmbH
  • PathWorks Diagnostics
  • Pfizer
  • PharmaTech Solutions, Inc.
  • PointCare Technologies Inc
  • Polymer Technology Systems Inc
  • Portola Pharmaceuticals
  • Procter and Gamble (P&G)
  • Prometheus Laboratories
  • Proteome Systems
  • Qiagen N.V.
  • Quest Diagnostics
  • QuickMedical
  • Quidel Corporation
  • Radiometer Medical ApS
  • Remel
  • Response Biomedical Corporation
  • Roche
  • Roche Diabetes Care (RDC)
  • Roche Diagnostics Corporation
  • Roche Holdings
  • Royal Philips Electronics
  • Runbio Biotech Company
  • SA Scientific
  • Sanofi
  • Savyon Diagnostics
  • Sekisui Medical Company
  • Siemens
  • Siemens AG
  • Siemens Diagnostics
  • Siemens Healthcare Diagnostics
  • Spirit Healthcare
  • STARLIMS Technologies
  • Suyog Diagnostics
  • Swiss Precision Diagnostics GmbH (SPD)
  • Symphony
  • Sysmex
  • SysmexCorporationThermo Scientific
  • T2 BioSystems
  • Teva
  • Therapeomics
  • Thermo Cardiosystems
  • Thermo Electron Corporation
  • Thermo Fisher Scientific Inc
  • Thoratec Corporation
  • Tocagen
  • Transasia Bio-Medicals
  • Triage
  • Trinity Biotech
  • Trovagene
  • U.S. Diagnostics
  • UL International GmbH
  • Universal Biosensors (UBI)
  • Universal Diagnostics
  • Ventana
  • Vermillion
  • Wall Greens
  • Wal-mart
  • Warburg Pincus
  • Wave 80 Biosciences
  • Werfen Group
  • Wilex
  • YD Diagnostics
  • Ypsomed
  • Zyomyx

Other Organisations Mentioned in This Report

  • American Diabetes Association
  • American Heart Association (AHA)
  • American Screening Corporation
  • AntiCoagulation Europe
  • AntiCoagulation Self-Monitoring Alliance (ACSMA)
  • Atrial Fibrillation Association
  • Baylor College of Medicine
  • Burnet Institute
  • Cambridge Sensors Limited
  • Centers for Device and Radiological Health (CDRH)
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare & Medicaid Services (CMS)
  • Children's Heart Federation
  • Clinical Laboratory Improvement Amendments (CLIA)
  • College of American Pathologists
  • Constitution Medical Investors
  • Department of Health and Human Services (HHS)
  • EU Council Directive
  • EU Notified Body
  • European Commission
  • European Diagnostics Manufacturers Association (EDMA)
  • Federal Joint Committee
  • Food and Drug Administration (FDA)
  • French Blood Establishment
  • Gemeinsamer Bundesausschuss
  • German Federal Ministry of Health
  • Harvard Salud Integral
  • In Vitro Diagnostic Device Evaluation and Safety (OIVD)
  • International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)
  • International Technidyne Corporation (ITC)
  • Japan's Ministry of Health
  • La Federación Española de Asociaciones de Anticoagulados (FEASAN)
  • Massachusetts General Hospital
  • MATCH Group
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mount Sinai School of Medicine
  • National Health Service (NHS)
  • National Innovation Centre
  • National Institutes of Health (NIH)
  • Northwestern Global Health Foundation
  • Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
  • Princenton BioMedtech
  • The Atrial Fibrillation Association
  • The Bill & Melinda Gates Foundation
  • The Centers for Disease Control and Prevention
  • The Centre for Disease Control (CDC)
  • The Children's Heart Federation
  • The College of American Pathologists
  • The European Directive
  • The European Society of Cardiology
  • The International Diabetes Federation (IDF)
  • The MATCH Group
  • The Mechanical Heart Valve Support Group
  • The National Institute for Health and Clinical Excellence (NICE)
  • The PATH's Diagnostics Group
  • UNAIDS
  • Unimed International
  • UNITAID
  • Universidad Peruana Cayetano Heredia
  • University of California
  • University of Cape Town and National Health Laboratory Service
  • US Department of Defense (DoD)
  • World Health Organization (WHO)
  • WorldCare International Clinical Trials
Back to Top